Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab + TTT for Neovascular AMD
NCT00599222Phase 3Completed
- Start
- Feb 2008
- Primary completion
- Nov 2009
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ranibizumab in neovascular age-related macular degeneration (NVAMD). Started Feb 2008; status: completed.
02
Drugs
ranibizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT00599222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00599222.